BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16970273)

  • 1. Comparison between F-18-FDG positron emission tomography and histology for the assessment of tumor necrosis rates in primary osteosarcoma.
    Huang TL; Liu RS; Chen TH; Chen WY; Hsu HC; Hsu YC
    J Chin Med Assoc; 2006 Aug; 69(8):372-6. PubMed ID: 16970273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis.
    Franzius C; Sciuk J; Brinkschmidt C; Jürgens H; Schober O
    Clin Nucl Med; 2000 Nov; 25(11):874-81. PubMed ID: 11079583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
    Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
    J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of chemotherapy response in osteosarcoma with FDG-PET.
    Hamada K; Tomita Y; Inoue A; Fujimoto T; Hashimoto N; Myoui A; Yoshikawa H; Hatazawa J
    Ann Nucl Med; 2009 Jan; 23(1):89-95. PubMed ID: 19205843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET.
    Schulte M; Brecht-Krauss D; Werner M; Hartwig E; Sarkar MR; Keppler P; Kotzerke J; Guhlmann A; Delling G; Reske SN
    J Nucl Med; 1999 Oct; 40(10):1637-43. PubMed ID: 10520703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of tumour necrosis fractions using metabolic and volumetric 18F-FDG PET/CT indices, after one course and at the completion of neoadjuvant chemotherapy, in children and young adults with osteosarcoma.
    Im HJ; Kim TS; Park SY; Min HS; Kim JH; Kang HG; Park SE; Kwon MM; Yoon JH; Park HJ; Kim SK; Park BK
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):39-49. PubMed ID: 21953008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [F-18]-fluorodeoxy-D-glucose-positron emission tomography response is associated with outcome for extremity osteosarcoma in children and young adults.
    Hawkins DS; Conrad EU; Butrynski JE; Schuetze SM; Eary JF
    Cancer; 2009 Aug; 115(15):3519-25. PubMed ID: 19517457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of chemotherapy response by PET-CT in osteosarcoma: correlation with histologic necrosis.
    Bajpai J; Kumar R; Sreenivas V; Sharma MC; Khan SA; Rastogi S; Malhotra A; Gamnagatti S; Kumar R; Safaya R; Bakhshi S
    J Pediatr Hematol Oncol; 2011 Oct; 33(7):e271-8. PubMed ID: 22193290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of chemotherapy response in pediatric bone sarcomas by [F-18]-fluorodeoxy-D-glucose positron emission tomography.
    Hawkins DS; Rajendran JG; Conrad EU; Bruckner JD; Eary JF
    Cancer; 2002 Jun; 94(12):3277-84. PubMed ID: 12115361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of osteogenic sarcoma to neoadjuvant therapy: evaluated by 18F-FDG-PET.
    Ye Z; Zhu J; Tian M; Zhang H; Zhan H; Zhao C; Yang D; Li W; Lin N
    Ann Nucl Med; 2008 Jul; 22(6):475-80. PubMed ID: 18670853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can pretreatment
    Song H; Jiao Y; Wei W; Ren X; Shen C; Qiu Z; Yang Q; Wang Q; Luo QY
    Eur Radiol; 2019 Jul; 29(7):3945-3954. PubMed ID: 30859285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ¹⁸F-FDG PET SUVmax as an indicator of histopathologic response after neoadjuvant chemotherapy in extremity osteosarcoma.
    Kong CB; Byun BH; Lim I; Choi CW; Lim SM; Song WS; Cho WH; Jeon DG; Koh JS; Yoo JY; Lee SY
    Eur J Nucl Med Mol Imaging; 2013 May; 40(5):728-36. PubMed ID: 23361860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of (18)F-FDG and (99m)Tc-methylene diphosphonate uptake in primary osteosarcoma.
    Franzius C; Bielack S; Flege S; Sciuk J; Jürgens H; Schober O
    J Nucl Med; 2002 Aug; 43(8):1012-7. PubMed ID: 12163625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.
    Hurley C; McCarville MB; Shulkin BL; Mao S; Wu J; Navid F; Daw NC; Pappo AS; Bishop MW
    Pediatr Blood Cancer; 2016 Aug; 63(8):1381-6. PubMed ID: 27082077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET response to neoadjuvant chemotherapy for Ewing sarcoma and osteosarcoma are different.
    Gaston LL; Di Bella C; Slavin J; Hicks RJ; Choong PF
    Skeletal Radiol; 2011 Aug; 40(8):1007-15. PubMed ID: 21298431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of different osteosarcoma phenotypes by PET imaging in preclinical animal models.
    Campanile C; Arlt MJ; Krämer SD; Honer M; Gvozdenovic A; Brennecke P; Fischer CR; Sabile AA; Müller A; Ametamey SM; Born W; Schibli R; Fuchs B
    J Nucl Med; 2013 Aug; 54(8):1362-8. PubMed ID: 23801674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
    Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
    J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (18)F and (18)FDG PET imaging of osteosarcoma to non-invasively monitor in situ changes in cellular proliferation and bone differentiation upon MYC inactivation.
    Arvanitis C; Bendapudi PK; Tseng JR; Gambhir SS; Felsher DW
    Cancer Biol Ther; 2008 Dec; 7(12):1947-51. PubMed ID: 18981708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is [F-18]-fluorodeoxy-D-glucose positron emission tomography of value in the management of patients with craniofacial bone sarcomas undergoing neo-adjuvant treatment?
    Frezza AM; Beale T; Bomanji J; Jay A; Kalavrezos N; Dileo P; Whelan J; Strauss SJ
    BMC Cancer; 2014 Jan; 14():23. PubMed ID: 24422949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.